gdc
FDA Approvals, News & UpdatesLung CancerNewsworthy

Tagrisso Now Approved as First Treatment for Metastatic NSCLC and EGFR Mutations

November 2018 Volume 4 – Lung Cancer

Patients who received Tagrisso had a longer period (18.9 months) without cancer progression versus 10.2 months with Iressa (gefitinib) or Tarceva (erlotinib). Among the patients who

responded to treatment, the average duration of response was 17.6 months with Tagrisso versus 9.6 months with Iressa or Tarceva.

The most common side effects with Tagrisso are diarrhea, rash, dry skin, and decreased appetite.

Share this:

Recommended For You
FDA Approvals, News & UpdatesLymphoma
FDA Approved Breyanzi, Novel Gene Therapy, for Large B-Cell Lymphoma
In February 2021, the FDA approved Breyanzi (lisocabtagene maraleucel; from Juno Therapeutics), a new CAR T-cell therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy.
FDA Approvals, News & UpdatesFollicular LymphomaLymphoma
FDA Approved Ukoniq, New Targeted Therapy, for Marginal-Zone and Follicular Lymphoma
In February 2021, the FDA approved Ukoniq (umbralisib; from TG Therapeutics), an oral kinase inhibitor, for the treatment of adults with relapsed or refractory marginal-zone lymphoma (MZL) or with relapsed or refractory follicular lymphoma.
FDA Approvals, News & UpdatesFollicular Lymphoma
Yescarta First Gene Therapy Approved for Follicular Lymphoma
In March 2021, the FDA approved a new indication for Yescarta (axicabtagene ciloleucel; from Kite Pharma), a CAR T-cell therapy, for the treatment of patients with relapsed or refractory follicular lymphoma who have received 2 or more lines of systemic therapy.
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approves Abecma, First CAR T-Cell Therapy for Multiple Myeloma
In March 2021, the FDA approved Abecma (idecabtagene vicleucel; from Bristol Myers Squibb/Bluebird Bio), a BCMA-directed, genetically modified CAR T-cell therapy, for the treatment of adults with multiple myeloma whose disease did not respond to, or returned, after 4 or more lines of therapy.
Last modified: December 11, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country